case_images: PMC10966921_01
case_images: Normalized average anti-FimH IgG Optical Density (OD) for serum samples collected pre-vaccination (Day 0), at month 1 (prior to FimCH vaccine dose #2), month 6 (prior to FimCH vaccine dose #4, month 7 (30 days post FimCH vaccine dose #4), and year 5 (approximately 4 years post FimCH vaccine dose #4). Vaccine dosing is indicated by   Day 1, Day 30, Day 90 and Day 180 on study for each participant.
case_images: fimmu-15-1359738-g001.jpg
case_images: PMC10966921_04_fimmu-15-1359738-g001.jpg
case_images: f1
case_images: The decrease in symptomatic culture-verified UTI occurrences correlates with observed peak anti-FimH antibody responses (Figure 1). Figure 1 for normalized average OD for serum samples diluted 1:25,000. For all participants, data trends indicate that anti-FimH IgG titers progressively increased after each vaccine injection with peak antibody responses observed at month 7, approximately 1 month following the fourth vaccine in the series.
case_images: PMC10966921_02
case_images: Normalized average anti-FimH IgG Optical Density (OD) for serum samples collected pre-vaccination (Day 0), at month 1 (prior to FimCH vaccine dose #2), month 6 (prior to FimCH vaccine dose #4, month 7 (30 days post FimCH vaccine dose #4), and year 5 (approximately 4 years post FimCH vaccine dose #4). Vaccine dosing is indicated by   Day 1, Day 30, Day 90 and Day 180 on study for each participant.
case_images: fimmu-15-1359738-g001.jpg
case_images: PMC10966921_04_fimmu-15-1359738-g001.jpg
case_images: f1
case_images: The decrease in symptomatic culture-verified UTI occurrences correlates with observed peak anti-FimH antibody responses (Figure 1). Figure 1 for normalized average OD for serum samples diluted 1:25,000. For all participants, data trends indicate that anti-FimH IgG titers progressively increased after each vaccine injection with peak antibody responses observed at month 7, approximately 1 month following the fourth vaccine in the series.
case_images: PMC10966921_03
case_images: Normalized average anti-FimH IgG Optical Density (OD) for serum samples collected pre-vaccination (Day 0), at month 1 (prior to FimCH vaccine dose #2), month 6 (prior to FimCH vaccine dose #4, month 7 (30 days post FimCH vaccine dose #4), and year 5 (approximately 4 years post FimCH vaccine dose #4). Vaccine dosing is indicated by   Day 1, Day 30, Day 90 and Day 180 on study for each participant.
case_images: fimmu-15-1359738-g001.jpg
case_images: PMC10966921_04_fimmu-15-1359738-g001.jpg
case_images: f1
case_images: The decrease in symptomatic culture-verified UTI occurrences correlates with observed peak anti-FimH antibody responses (Figure 1). Figure 1 for normalized average OD for serum samples diluted 1:25,000. For all participants, data trends indicate that anti-FimH IgG titers progressively increased after each vaccine injection with peak antibody responses observed at month 7, approximately 1 month following the fourth vaccine in the series.
case_images: PMC10966921_04
case_images: Normalized average anti-FimH IgG Optical Density (OD) for serum samples collected pre-vaccination (Day 0), at month 1 (prior to FimCH vaccine dose #2), month 6 (prior to FimCH vaccine dose #4, month 7 (30 days post FimCH vaccine dose #4), and year 5 (approximately 4 years post FimCH vaccine dose #4). Vaccine dosing is indicated by   Day 1, Day 30, Day 90 and Day 180 on study for each participant.
case_images: fimmu-15-1359738-g001.jpg
case_images: PMC10966921_04_fimmu-15-1359738-g001.jpg
case_images: f1
case_images: The decrease in symptomatic culture-verified UTI occurrences correlates with observed peak anti-FimH antibody responses (Figure 1). Figure 1 for normalized average OD for serum samples diluted 1:25,000. For all participants, data trends indicate that anti-FimH IgG titers progressively increased after each vaccine injection with peak antibody responses observed at month 7, approximately 1 month following the fourth vaccine in the series.